



(51) International Patent Classification:

C07C 275/24 (2006.01) A61K 31/17 (2006.01)
C07C 275/16 (2006.01) A61P 11/00 (2006.01)
C07C 273/02 (2006.01)

(21) International Application Number:

PCT/US2010/043783

(22) International Filing Date:

29 July 2010 (29.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/231,660 5 August 2009 (05.08.2009) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street, Suite 100, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STEARNS, Brian, Andrew** [US/US]; 157 Beechtree Drive, Encinitas, California 92024 (US). **KING, Christopher, David** [US/US]; 7396 Escallonia Court, Carlsbad, California 92011 (US). **BRITTAIN, Jason, Edward** [US/US]; 1580 Chiswick Court, El Cajon, California 92020 (US). **HOLME, Kevin, Ross** [US/US]; 13644 Landfair Road, San Diego, California 92130 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: DP₂ ANTAGONIST AND USES THEREOF




Figure 1.

(57) Abstract: Described herein is the DP₂ antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP₂ antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP₂ antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D₂-dependent or prostaglandin D₂-mediated diseases or conditions.